In a few weeks’ time, industry’s foremost drug developers will be convening at the 5th Genome Editing Therapeutics Summit* (December 3-5 | Boston, MA), the only industry meeting dedicated to sharing invaluable insights to help progress gene editing programs into the clinic. *Formerly known as the CRISPR 2.0 Summit
In a recent interview with the Genome Editing Therapeutics Summit Team, Jeffrey Cehelsky, VP Development Operations of Intellia Therapeutics shared insights on questions such as:
What are some of the top challenges associated with running smooth clinical trials in this modality compared to others you have worked with?
What are the key development and operational considerations associated with making the leap to Phase III studies?
Where does the field need to make progress to take the exciting, emerging technologies we see in R&D and translate them into viable therapies?
Read the full interview here to uncover Jeff’s answers.
120 senior industry figures from the likes of Intellia, Vertex, Prime, Nvelop and Tessera will join Jeff at the 5th Genome Editing Therapeutics Summit in December, sharing case-study led solutions to the drug development challenges they are working through. Register here to join them too.